Safety Study of CALAA-01 to Treat Solid Tumor Cancers

Clinical Trial ID NCT00689065

PubWeight™ 61.95‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00689065

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010 10.09
2 Delivery materials for siRNA therapeutics. Nat Mater 2013 3.70
3 RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 2012 3.70
4 Targeted polymeric therapeutic nanoparticles: design, development and clinical translation. Chem Soc Rev 2012 3.34
5 RNA-based therapeutics: current progress and future prospects. Chem Biol 2012 3.01
6 Therapeutic genome editing: prospects and challenges. Nat Med 2015 2.42
7 A status report on RNAi therapeutics. Silence 2010 2.18
8 Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 2010 1.88
9 The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2011 1.64
10 Progress toward in vivo use of siRNAs-II. Mol Ther 2011 1.60
11 Apoptosis and molecular targeting therapy in cancer. Biomed Res Int 2014 1.47
12 Molecular imaging with theranostic nanoparticles. Acc Chem Res 2011 1.41
13 RNAi therapies: drugging the undruggable. Sci Transl Med 2014 1.26
14 An RNA alternative to human transferrin: a new tool for targeting human cells. Mol Ther Nucleic Acids 2012 1.25
15 Apoptotic cell signaling in cancer progression and therapy. Integr Biol (Camb) 2011 1.22
16 Targeted therapy using nanotechnology: focus on cancer. Int J Nanomedicine 2014 1.22
17 Nanoparticle-Based Delivery of RNAi Therapeutics: Progress and Challenges. Pharmaceuticals (Basel) 2013 1.21
18 Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther 2012 1.19
19 Advances in polymeric and inorganic vectors for nonviral nucleic acid delivery. Ther Deliv 2011 1.17
20 STAT inhibitors for cancer therapy. J Hematol Oncol 2013 1.16
21 Cancer nanomedicine: from targeted delivery to combination therapy. Trends Mol Med 2015 1.13
22 Clinical experiences with systemically administered siRNA-based therapeutics in cancer. Nat Rev Drug Discov 2015 1.02
23 Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 2015 1.01
24 Advances of cancer therapy by nanotechnology. Cancer Res Treat 2009 1.01
25 Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol 2009 0.98
26 Functional lipids and lipoplexes for improved gene delivery. Biochimie 2011 0.96
27 Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. Nanomedicine (Lond) 2014 0.94
28 Clinical Translation of Nanomedicine. Chem Rev 2015 0.93
29 Nanotechnology: Future of Oncotherapy. Clin Cancer Res 2015 0.86
30 Biotargeted nanomedicines for cancer: six tenets before you begin. Nanomedicine (Lond) 2013 0.85
31 Small interfering RNA-based molecular therapy of cancers. Chin J Cancer 2013 0.83
32 Lipid-Based Nanocarriers for RNA Delivery. Curr Pharm Des 2015 0.81
33 Nanoparticle ligand presentation for targeting solid tumors. AAPS PharmSciTech 2014 0.80
34 Nanoparticle-based targeted therapeutics in head-and-neck cancer. Int J Med Sci 2015 0.79
35 Targeted polymeric nanoparticles for cancer gene therapy. J Drug Target 2015 0.78
36 Fighting against kidney diseases with small interfering RNA: opportunities and challenges. J Transl Med 2015 0.78
37 Nanomedicine in chemoradiation. Ther Deliv 2013 0.78
38 MicroRNA--managing the TH-17 inflammatory response. Nat Immunol 2009 0.76
39 Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment. Cancer Treat Rev 2016 0.76
40 Tackling breast cancer chemoresistance with nano-formulated siRNA. Gene Ther 2016 0.75
41 RNA interference in head and neck oncology. Oncol Lett 2016 0.75
Next 100